# Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

> **NCT02644941** · PHASE3 · COMPLETED · sponsor: **Humacyte, Inc.** · enrollment: 355 (actual)

## Conditions studied

- Renal Failure
- End Stage Renal Disease
- Hemodialysis
- Vascular Access

## Interventions

- **BIOLOGICAL:** Human Acellular Vessel (HAV)
- **DEVICE:** ePTFE graft

## Key facts

- **NCT ID:** NCT02644941
- **Lead sponsor:** Humacyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-24
- **Primary completion:** 2019-05
- **Final completion:** 2023-09
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644941, "Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02644941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*